Hepatitis C virus core protein: An update on its molecular biology, cellular functions and clinical implications

Medical Principles and Practice

Volumn 15, Issue 6, 2006, Pages 405-416

  Irshad, M ^a   Dhar, Indranil ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Apoptosis; Core protein; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

CORE PROTEIN;

AMINO ACID SEQUENCE; APOPTOSIS; CARCINOGENESIS; CELL FUNCTION; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOMODULATION; LIVER CELL CARCINOMA; MOLECULAR BIOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; VACCINATION; VIRUS GENOME; VIRUS REPLICATION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MOLECULAR BIOLOGY; OXIDATIVE STRESS; VIRAL CORE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 33749831058     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095485     Document Type: Review

References (129)

1. Koike K, Tsutsumi T, Fujie H, Yoshizumi S, Moriya K: Molecular mechanism of viral hepatocarcinogenesis. Oncology 2002;62:29-37.
2. Brinster C, Inchauspe G: DNA vaccine for hepatitis-C virus. Immunology 2001;44:143-153.
3. Alter HJ: To C or not to C: these are the questions. Blood 1995;85:1681-1695.
4. WHO: Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72:341-348.
5. Drazan KE: Molecular biology of hepatitis-C infection. Liver Transpl 2000;6:396-406.
6. Choo QL, Kuo G, Weiner AJ, Overby L, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
7. Choo Q-L, Richman K, Han J, Berger K, Lee C, Dong C, Gallegos D, Coit D, Medina-Selly A, Barr P, Weiner A, Bradley D, Kuo G, Houghton M: Genetic organization and diversity of the hepatitis-C virus. Proc Natl Acad Sci USA 1991;88:2451-2455.
8. Simmonds P, Holmes EC, Cha TA, Chan S-W, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS: Classification of hepatitis-C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-2399.
9. Bukh J, Miller R, Purcell R: Genetic Heterogenicity of hepatitis-C virus: Quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
10. Wang C, Sarnow P, Siddiqui A: A conserved helical element is essential for internal initiation of translation of hepatitis-C virus RNA. J Virol 1994;68:7301-7307.
11. Yanagi M, St Claire M, Emerson SU, Purcell RH, Bukh J: In-vivo analysis of the 3′ untranslated region of the hepatitis-C virus after in-vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci USA 1999;96:2291-2295.
12. Houghton M: Hepatitis C viruses; in Fields BN, Knipe DM, Howley PM (eds): Fields Virology, 3rd ed. Philadelphia, Lippincott-Raven, 1996, pp 1035-1058.
13. Lin C, Pragai BM, Grakoui A, Xu J and Rice CM: Hepatitis-C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics. J Virol 1994;68:5063-5073.
14. Santolini E, Migliaccio G, Monica NL: Biosynthesis and biochemical properties of the hepatitis-C virus core protein. J Virol 1994;68:3631-3641.
15. Ray RB, Lagging LM, Meyer K, Steele R, Ray R: Transcriptional regulation of cellular and viral promoters by the hepatitis-C virus core protein. Virus Res 1995;37:209-220.
16. McLauchlan J: Properties of the hepatitis-C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 2000;7:2-14.
17. Kunkel M, Lorinezi M, Rijinbrand R, Lemon SM, Watowich SJ: Self-assembly of nucleocapsid-like particles from recombinant hepatitis-C virus core protein. J Virol 2001;75:2119-2129.
18. Kunkel M, Watowich SJ: Conformational changes accompanying self-assembly of the hepatitis-C virus core protein. Virology 2002;294:239-245.
19. Fan Z, Yang QR, Twu JS, Sherker AH: Specific in-vitro association between the hepatitis-C viral genome and core protein. J Med Virol 1999;59:131-134.
20. Tanaka Y, Shimoike T, Ishii K, Suzuki R, Suzuki T, Ushijima H, Matsuura Y, Miyamura T: Selective binding of hepatitis-C virus core protein to synthetic oligonucleotides corresponding to the 5′ untranslated region of the viral genome. Virology 2000;270:229-236.
21. Matsumoto M, Hwang SB, Jeng KS, Zhu N, Lai MM: Homotypic interaction and multimerization of hepatitis-C virus core protein. Virology 1996;218:43-51.
22. Nolandt O, Kern V, Muller H, Pfaff E, Theilmann L, Welker R, Krausslich HG: Analysis of hepatitis-C virus core protein interaction domains. J Gen Virol 1997;78:1331-1340.
23. Lo SY, Selby MJ, Ou JH: Interaction between hepatitis-C virus core protein and E1 envelope protein. J Virol 1996;70:5177-5182.
24. Ravaggi A, Natoli G, Primi D, Albertini A, Levero M, Cariani J: Intracellular localization of full-length and truncated hepatitis-C virus core protein expressed in mammalian cells. J Hepatol 1994;20:833-836.
25. Suzuki R, Matsuura Y, Suzuki T, Ando A, Chiba J, Harada S, Saito I, Miyamura T: Nuclear localization of the truncated hepatitis-C virus core protein with its hydrophobic C terminus deleted. J Gen Virol 1995;76:53-61.
26. Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Wase C, Lai MM: Hepatitis-C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998;72:3691-3697.
27. Chen CM, You LR, Hwang LH, Lee YH: Direct interaction of hepatitis-C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor J Virol 1997;71:9417-9426.
28. Mamiya N, Worman HJ: Hepatitis-C virus core protein binds to a DEAD box RNA helicase. J Biol Chem 1999;274:15751-15756.
29. Owslanka AM, Patel AH: Hepatitis-C virus core protein interacts with a human DEAD box protein DDX3. Virology 1999;257:330-340.
30. Hseih TY, Matsumoto M, Chou HC, Schneider R, Hwang SB, Lee AS, Lai MM: Hepatitis-C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K. J Biol Chem 1998;273:17651-17659.
31. Wang F, Yoshida I, Takamatsu M, Ishido S, Fujita T, Oka K, Hotta H: Complex formation between hepatitis-C virus core protein and p21Wat/Cip1/Sid.1. Biochem Biophys Res Commun 2000;273:479-484.
32. Lu W, Lo S, Chen M, Wu K, Fung YKT, Ou J: Activation of p53 tumor suppressor by Hepatitis-C virus core protein. Virology 1999;264:134-141.
33. Jin DY, Wang HL, Zhou Y, Chun AC, Kibler KV, Hou YD, Kung H, Jeang KT: Hepatitis-C virus core protein-induced loss of LZIP function correlates with cellular transformation. EMBO J 2000;19:729-740.
34. Kato N, Yoshida H, Kioko Ono-Nita S, Kato J, Goto T, Otsuka M, Lan K, Matsushima K, Shiratori Y, Omata M: Activation of intracellular signaling by hepatitis B and C viruses, C-viral core is the most potent signal inducer. Hepatology 2000;32:405-412.
35. Naganuma A, Nozaki A, Tanaka T, Sugiyama K, Takagi H, Mori M, Shimotoohno K, Kato N: Activation of the interferon inducible 2′-5′- oligoadenylate synthetase gene by hepatitis-C virus core protein. J Virol 2000;74:8744-8750.
36. Otsuka M, Kato N, Lan KH, Yoshida H, Kato J, Goto T, Shiratori Y, Omata M: Hepatitis-C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem 2000;275:34122-34130.
37. Hahn CS, Cho YG, Kang BS, Lester IM, Hahn YS: The HCV core protein acts as a positive regulator of fas-mediated apoptosis in a human lymphoblastoid T-cell line. Virology 2000;276:127-137.
38. Ray RB, Meyer K, Ray R: Suppression of apoptotic cell death by hepatitis-C virus core protein. Virology 1996;226:176-182.
39. Marusawa H, Hijikata M, Chiba T, Shimotohno K: Hepatitis-C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol 1999;73:4713-4720.
40. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K: Hepatitis-C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997;78:1527-1531.
41. Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, Nomura S, Chayama K: Hepatitis-C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 2005;50:1361-1371.
42. Goh PY, Tan YJ, Lim SP, Lim SG, Tan YH, Hong WJ: The hepatitis-C virus core protein interacts with NS5A and activates its caspase mediated proteolytic cleavage. Virology 2001;290:224-236.
43. Moradpour D, Englert C, Wakita T, Wands JR: Characterization of cell lines allowing tightly regulated expression of hepatitis-C virus core protein. Virology 1996;222:51-63.
44. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Brechot C: Hepatitis-C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997;94:1200-1205.
45. Satoh S, Hirota M, Noguchi T, Hijikata M, Handa H, Shimitohno K: Cleavage of Hepatitis-C virus nonstructural protein. Virology 2000;229:68-76.
46. Ruggleri A, Harada T, Matsuura Y, Miyamura T: Sensitization to Fas-mediated apoptosis by hepatitis-C virus core protein. Virology 1997;229:68-76.
47. Roulston A, Marcellus RC, Branton PE: Viruses and apoptosis. Ann Rev Microbiol 1999;53:577-628.
48. Liu Q, Tackney C, Bhat RA, Prince AM, Zhang P: Regulated processing of hepatitis-C virus core protein is linked to subcellular localization. J Virol 1997;71:657-662.
49. Liao QJ, Ye LB, Timani KA, She YL, Yang XJ, Ye L, Wu ZH: Hepatitis-C virus non-structural 5A protein can enhance full-length core protein-induced nuclear factor-kappaB activation. World J Gastroenterol 2005;11:6433-6439.
50. Kountouras J, Zavos C, Chatzopoulos D: Apoptosis in hepatitis-C. J Viral Hepat 2003;10:335-342.
51. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaseli KJ, Debatin, KM, Krammer PH, Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-1687.
52. Porteu A, Henrion A, Bouscary D, Varlet P, Rouquet N, Molina T: Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 1996;2:80-86.
53. Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326.
54. Chinnaiyan AM, Orth K, O'Rourke K, Duan H, Poiner GG, Dixit VM: Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic protease. J Biol Chem 1996;271:4573-4576.
55. Erhardt P, Cooper GM: Activation of the CPP 32 apoptone protease by distinct signaling pathways with differential sensitivity to Bcl-xL. J Biol Chem 1996;271:17601-17604.
56. Shimiz S, Eguchi Y, Kamiike W, Matsuda H, Tsujimoto Y: Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene 1996;13:21-29.
57. You LR, Chen CM, Lee YHW: Hepatitis-C virus core protein enhances NF-kappaB signal pathway triggering by lymphotoxin-beta receptor ligand and tumor necrosis factor alpha. J Virol 1999;73:1672-1681.
58. Yoshida H, Kato N, Shiratori Y, Otsuka M, Meeda S, Kato J, Omata M: Hepatitis-C virus core protein activates nuclear factor kappaB-dependent signaling through tumor necrosis factor receptor-associated factor. J Biol Chem 2001;276:16399-16405.
59. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr: NF-kappaB antiapoptosis. Induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-1683.
60. Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF: IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science 1998;281:998-1001.
61. Grumont RJ, Rourke IJ, Gerondakis S: Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999;13:400-411.
62. Hettmann T, DiDonato J, Karin M, Leiden JM: An essential role for nuclear factor kappaB in promoting double positive thymocyte apoptosis. J Exp Med 1999;189:145-158.
63. Cerny A, Chisari FV: Pathogenesis of chronic hepatitis-C Immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595-601.
64. Matsuura K, Kimura Y, Miyamura ST, Koike K: The core protein of hepatitis-C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-1067.
65. Soguero C, Joo M, Chianese-Bullock KA, Nguyen DT, Tung K, Hahn YS: Hepatitis-C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol 2002;76:9345-9354.
66. Kimball P, Verbeke S, Shiffman M: HCV core protein augments cyclosporine immunosuppression. Transplant Proc 2005;37:652-653.
67. Gehring S, Gregory SH, Kuzushita N, Wands JR: Type 1 interferon augments DNA-based vaccination against hepatitis-C virus core protein. J Med Virol 2005;75:249-257.
68. Chou AH, Tsai HF, Wu YY, Hu CY, Hwang LH, Hsu PI, Hsu PN: Hepatitis-C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 2005;174:2160-2166.
69. Li W, Li J, Tyrrell DL, Agrawal B: Expression of hepatitis-C virus-derived core or NS3 antigens in human dendritic cells leads to induction of pro-inflammatory cytokines and normal T-cell stimulation capabilities. J Gen Virol 2006;87:61-72.
70. Sundstrom S, Ota S, Dimberg LY, Masucci MG, Bergqvist A: Hepatitis-C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses. J Virol 2005;79:2230-2239.
71. Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H: Benefit of hepatitis-C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 2005; 43:186-191.
72. Cooper S, Erikson AL, Adams EJ, Kansopon J, Weiner AJ, Chen DY, Houghton M, Parham P, Walker CM: Analysis of a successful immune response against hepatitis-C virus. Immunity 1999;10:439-449.
73. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, Houghton M, Fiaccadori F, Ferrari C: Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98:706-714.
74. Chang KM, Gruener NH, Southwood S, Sidney J, Pape GR, Chang FV, Sette A: Identification of HLA-A3 and B7-restricted CTL responses hepatitis-C virus in patients with acute and chronic hepatitis-C. J Immunol 1999;162:1156-1164.
75. Sabile A, Perlemuter G, Bono F, Kohara K, Demaugre F, Kotex M, Matsuura Y, Miyamura T, Brechot C, Barba G: Hepatitis-C virus core protein binds to apolipoprotein All and its secretion is modulated by fibrates. Hepatology 1999;30:1064-1076.
76. Hijikata M, Mizushima H, Akagi T, Mori S, Kakkiuchi N, Kato N, Tanga T, Kimura K, Shimotohno K: Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis-C virus. J Virol 1999;67:4665-4675.
77. Kanto T, Hayashi N, Takehara T, Hagiwara H, Mita E, Nate M, Kasahara A, Fusamoto H, Kamada T: Buoyant density of hepatitis virus recovered from infected hosts: two different features in sucrose equipment density-gradient centrifugation related to degree of liver inflammation. Hepatology 1994;19:296-302.
78. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yen S: Development of a simple and highly sensitive enzyme immunoassay for hepatitis-C virus core antigen. J Clin Microbiol 1999;37:1802-1808.
79. Urushihara A, Sodeyama T, Matsumoto A, Tanaka E. Changes in antibody titres to hepatitis-C virus following interferon therapy for chronic infection. J Med Virol 1994;42:348-356.
80. Ray RB, Meyer K, Steele R, Shrivastava A, Aggarwal BB, Ray R: Inhibition of tumor necrosis factor (TNF-alpha) mediated apoptosis by hepatitis-C virus. J Biol Chem 1998;273:2256-2259.
81. Large M, Kittlesen D, Hahn Y: Suppression of host immune response by the core protein of hepatitis-C virus. Possible implications for hepatitis-C virus persistence. J Immunol 1999;162:931-938.
82. Matsumoto M, Hsieh TY, Zhu N, Vanarsdale T, Hwang SB, Jeng KS, Gorbalenya AE, Lo SY, Ou JH, Ware CF, Lai MMC: Hepatitis-C virus core protein interacts with the cytoplasmic tail of lymphotoxin-β receptor. J Virol 1997;71:1301-1309.
83. Kroemer G: Mitochondrial control of apoptosis: an overview. Biochem Soc Symp 1999;66:1-15.
84. Machida K, Tsukiyama-Kohara K, Seike E, Tone S, Shibasaki F, Shimizu M, Takahashi H, Hayashi Y, Funata N, Taya C, Yonekawa H, Kohara M: Inhibition of cytochrome c release in Fas-mediated signalling pathway in transgenic mice induced to express hepatitis-C viral proteins. J Biol Chem 2001;276:12140-12146.
85. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis-C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-1067.
86. 2+ responses. Science 1998;280:1763-1766.
87. Okuda M, Li K, Beard MR, Showalter LA, Schole F, Lemon SM, Weinman SA: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis-C virus core protein. Gastroenterology 2002;122:366-375.
88. Majander A, Finel M, Wikstrom M: Diphenyleneiodonium inhibits reduction of iron-sulfur clusters in the mitochondrial NADH-ubiquinone oxidoreductase (complex I). J Biol Chem 1994;269:21037-21042.
89. Baley SM, Pietsch EC, Cunningham CC: Ethanol stimulates the production of reactive oxygen species at mitochondrial complexes I and III. Free Radic Biol Med 1992;27:891-900.
90. Cai J, Jones DP: Mitochondrial redox signaling during apoptosis. J Bioenerg Biomembr 1999;31:327-334.
91. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K: Oxidative stress in the absence of inflammation in a mouse model for hepatitis-C virus-associated hepatocarcinogenesis. Cancer Res 2001;61:4365-4370.
92. Factor VM, Laskowska D, Jensen MR, Woltach JT, Popescu NC, Thorgeirsson SS: Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci USA 2000;97:2196-2201.
93. Lau JYN, Krawczynski K, Negro F, Gonzalez-Peralta RP: In situ detection of hepatitis-C virus: a critical appraisal. J Hepatol 1996;24:48-53.
94. Shimizu YK, Feinstone SM, Kohara M, Purcell RH, Yoshikura H: Hepatitis-C virus: detection of intracellular virus particles by electron microscopy. Hepatology 1996;23:205-209.
95. Agnello V, Knight AG, Munchmore E: Detection of widespread hepatocyte infection in chronic hepatitis-C. Hepatology 1998;28:573-584.
96. Hoofnagle JH: Hepatitis-C: The clinical spectrum of disease. Hepatology 1997;26:15S-20S.
97. Lerat A, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM: Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis-C virus. Gastroenterology 2002;122:352-365.
98. Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G: Review article: hepatitis-C virus-associated steatosis - pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 2005;22(suppl 2): 52-55.
99. Marreto JA, Fontana RJ, Su GL, et al: NAFLD may be a common underlying liver disease in patients with HCC in the United States. Hepatology 2002;36:1349-1354.
100. Lee MN, Jung EY, Kwun HJ, et al: Hepatitis-C virus core protein represses the p21 promotor thorough inhibition of a TGF-beta pathway. J Gen Virol 2002;83:2145-2151.
101. Kwun HJ, Jang KL: Dual effects of hepatitis-C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene. J Viral Hepat 2003;10:249-255.
102. Yamanaka T, Kodama T, Doi T: Subcellular localization of HCV CORE protein regulates its ability for p53 activation and p21 suppression. Biochem Biophys Res Commun 2002;294:528-534.
103. Zakut R, Givol D: The tumor suppression function of p21Waf is contained in its N-terminal half ('half-WAF'). Oncogene 1995;11:393-395.
104. Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P: Alternate translation occurs within the core coding region of the hepatitis-C viral genome. J Biol Chem 2002;277:17713-17721.
105. Benard J, Douc-Rasy S, Ahomadegbe JC: TP53 family members and human cancers. Hum Mutat 2003;21:182-191.
106. Davis GL: Hepatitis-C virus genotypes and quasispecies. Am J Med 1999;107:21S-26S.
107. Alisi A, Giambartolomei S, Cupelli F, et al: Physical and functional interaction between HCV core protein and the different p73 isoforms. Oncogene 2003;22:2573-2580.
108. Iwata K, Wakita T, Okumura A, Yoshioka K, Takayanagi M, Wands J, Kakumu S: Interferon gamma production by peripheral blood lymphocytes to hepatitis-C virus core protein in chronic hepatitis-C infection. Hepatology 1995;22:1057-1064.
109. Lasarte JJ, Garcia-Granero G, Lopez A, Casares N, Garcia N, Civeira MP, Borras-Cuesta F, Prieto J: Cellular immunity to hepatitis-C virus core protein and the response to interferon in patients with chronic hepatitis-C. Hepatology 1998;28:815-822.
110. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, Lau JYN: The role of hepatitis-C virus-specific cytotoxic T lymphocytes in chronic hepatitis-C. J Immunol 1997;158:1473-1481.
111. Lagging LM, Meyer K, Hoft D, Houghton M, Belshe RB, Ray R: Immune responses to plasmid DNA encoding the hepatitis-C virus core protein. J Virol 1995;69:5859-5863.
112. Hu GJ, Wang RYH, Han DS, Alter HJ, Shih WK: Characterization of the humoral and cellular immune responses against hepatitis-C virus core induced by DNA-based immunization. Vaccine 1999;17:3160-3170.
113. Geissler M, Tokushige K, Wakita T, Zurawski VR, Wands JR: Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunization using chimeric constructs. Vaccine 1998;16:857-867.
114. Inchauspe G, Vitvitski L, Major ME, Jung G, Spengeler U, Maisonnas M, Trepo C: Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis-C virus nucleocapsid: Comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997;16:182-195.
115. Major ME, Vitvitski L, Mink MA, Schleef M, Whalen RG, Trepo C, Inchauspe G: DNA based immunization with chimeric vectors for the induction of immune responses against the hepatitis-C virus nucleocapsid. J Virol 1995;69:5798-5805.
116. Vidalin O, Tanaka E, Spengler U, Trepo C, Inchauspe G: Targeting hepatitis-C virus core protein for MHC1 or MHCII presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol 1999;18:611-621.
117. Rodriguez F, Zhang J, Whitton J: DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997; 71:8497-8503.
118. Chen C, Ji H, Suh K, Choti M, Pardoll D, Wy T: Gene-gun mediated DNA vaccination induces antitumor immunity against human papillomarvirus type 16 E7-expressing murine tumours in the liver and lungs. Gene Ther 1999;6:1972-1981.
119. Ruff A, Guarnieri F, Stageley-O'Carroll K, Siliciano R, August J: The enhanced immune response to the HIV gp 160-LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J Biol Chem 1997;272:8671-8678.
120. Tanaka T, Lau JYN, Mizokami M, et al: Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis-C viremia. J Hepatol 1995;23:742-745.
121. Kashiwakuma T, Hasegawa A, Kajita T, et al: Detection of hepatitis-C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA). J Immunol Methods 1996;190:79-89.
122. Arduino JM, Stuver SO, Spiegelman D, et al: Assessment of markers of hepatitis-C virus infection in a Japanese adult. J Infect Dis 2001;184:1229-1235.
123. Zanetti AR, Romano I, Brunetto M, Colombo M, Belati G, Tackney C: Total HCV core antigen assay: a new marker of hepatitis-C viremia for monitoring the progress of therapy. J Med Virol 2003;70:27-30.
124. Megali Bouvier A, Patel K, Dahari H, Beaucourt S, et al. Clinical utility of total HCV core antigen quantification: A new indirect marker of HCV replication. Hepatology 2002;36:211-218.
125. Tanaka E, Ohue C, Aoyagi K, Yamanguchi K, Yagi S, Kiyosawa K, Alter HJ: Evaluation of a new enzyme immunoassay for hepatitis-C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2001;32:388-393.
126. Lindenbach BD, Rice CM: Unravelling hepatitis-C virus replication from genome to function. Nature 2005;436:933-938.
127. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Complete replication of hepatitis-C virus in cell culture. Science 2005;309:623-626.
128. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV: Robust hepatitis-C virus infection in-vitro. Proc Natl Acad Sci USA 2005;102:9294-9299.
129. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ: Production of infectious hepatitis-C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.